Cancer Research and Treatment

Original Articles

Time-Trend Analysis and Risk Factors for Niraparib-Induced Nausea and Vomiting in Ovarian Cancer: A Prospective Study: Young Wook Jeong, Dongkyu Eugene Kim, Ji Hyun Kim, Se Ik Kim, Hyeong In Ha, Sang-Yoon Park, Myong Cheol Lim; Received September 14, 2024 Accepted November 2, 2024 Published online November 4, 2024; DOI: https://doi.org/10.4143/crt.2024.899 [Epub ahead of print]

Abstract PDF Supplementary Material PubReader ePub: Purpose
Nausea and vomiting are major non-hematological adverse events associated with niraparib maintenance therapy. This study aimed to investigate the time-trend patterns of niraparib-induced nausea and vomiting (NINV) and the associated risk factors in patients with ovarian cancer.
Materials and Methods
In this prospective study, we enrolled patients with stage III-IV epithelial ovarian cancer who received niraparib as frontline maintenance therapy. The clinicopathological characteristics and time-trend patterns of patients with NINV were collected through in-person surveys and electronic medical records from the National Cancer Center.
Results
Of 53 patients, 50 (94.3%) were diagnosed with high-grade serous ovarian carcinoma. BRCA mutations and homologous recombination deficiency (HRD) were identifi ed in 23 (43.4%) and 32 (60.4%) patients, respectively. Thirty-one patients (58.5%) had NINV. Time-trend analyses revealed that the fi rst peak intensity of NINV was reached at 3 h post-dose, and the second peak intensity was reached at 11 hour post-dose. NINV signifi cantly decreased from week 1 to weeks 8 and 12. In multivariate analyses of risk factors for NINV, HRD-positive tumors (p < 0.001) and prior experience of chemotherapy-induced nausea and vomiting (p=0.004) were associated with the occurrence of NINV.
Conclusion
Pre-emptive treatment with antiemetics is required to manage early-phase NINV during niraparib maintenance therapy in patients with risk factors. Additional larger studies are needed to confi rm these fi ndings and to develop optimal preventive strategies for NINV.

1,327 View
182 Download

Gynecologic cancer

Uptake of Family-Specific Mutation Genetic Testing Among Relatives of Patients with Ovarian Cancer with BRCA1 or BRCA2 Mutation: Go Woon Jeong, Wonkyo Shin, Dong Ock Lee, Sang-Soo Seo, Sokbom Kang, Sang-Yoon Park, Myong Cheol Lim; Cancer Res Treat. 2021;53(1):207-211. Published online August 11, 2020; DOI: https://doi.org/10.4143/crt.2020.364

Abstract PDF PubReader ePub

Purpose
The BRCA1 or BRCA2 gene is transmitted in an autosomal dominant fashion, and genetic testing of first-degree relatives of patients with family-specific mutation (FSM) is recommended. This study examined factors affecting the uptake of FSM testing among relatives of patients with peritoneal, ovarian, or fallopian tube (POFT) cancer with confirmed BRCA1 or BRCA2 germline mutation.
Materials and Methods
Data from medical charts of 392 eligible patients and their relatives who had undergone outpatient genetic counseling/testing were retrospectively reviewed. Clinical factors were compared between family members who had and had not undergone genetic counseling/testing.
Results
The uptake of FSM testing was 30.5% (129/423) among first-degree living relatives and 53.5% (69/129) within the overall family unit. The average time from genetic testing of the proband to the first FSM test within a family was 168 days (range, 23 to 681 days). Having a living father (33.8% vs. 13.3%, p=0.007) and daughter (79.4% vs. 60.3%, p=0.019) increased the uptake of FSM testing. FSM testing was more likely among female than among male relatives of cancer patients (40.9% vs. 17.6%, p < 0.001).
Conclusion
Approximately one-third of first-degree relatives of patients with a POFT cancer with BRCA1 or BRCA2 mutation underwent FSM testing. Having a living father or daughter was a factor affecting the uptake of FSM testing, which was higher among female than among male relatives of the proband. This discrepancy might be due to a misconception that the BRCA gene is associated with women rather than with men.

Citations

Citations to this article as recorded by

Factors affecting the implementation of cascade testing of patients with BRCA1 or BRCA2 pathogenic germline variants in Japan
Yoshimi Kiyozumi, Seiichiro Nishimura, Nobuhiro Kado, Satomi Higashigawa, Yasue Horiuchi, Eiko Ishihara, Rina Harada, Hiroyuki Matsubayashi
Journal of Genetic Counseling.2025;[Epub] CrossRef
Cascade testing in Italian Hereditary Breast Ovarian Cancer families: a missed opportunity for cancer prevention?
Lucia Trevisan, Lea Godino, Linda Battistuzzi, Giovanni Innella, Elena Luppi, Giulia Buzzatti, Viviana Gismondi, Eva Blondeaux, Luigina Ada Bonelli, Daniela Turchetti, Liliana Varesco
Familial Cancer.2024; 23(2): 197. CrossRef
Cancer burden in individuals with single versus double pathogenic variants in cancer susceptibility genes
Nihat B. Agaoglu, Brittany L. Bychkovsky, Carolyn Horton, Min-Tzu Lo, Linda Polfus, Cassidy Carraway, Parichehr Hemyari, Colin Young, Marcy E. Richardson, Rochelle Scheib, Judy E. Garber, Huma Q. Rana
Genetics in Medicine Open.2024; 2: 101829. CrossRef
Streamlined Genetic Education and Cascade Testing in Men from Hereditary Breast Ovarian Cancer Families: A Randomized Trial
Christopher Grisham, Beth N. Peshkin, Lia Sorgen, Claudine Isaacs, Mary Kathleen Ladd, Aryana Jacobs, Savannah Binion, Mara Tynan, Emily Kuchinsky, Susan Friedman, Kathryn L. Taylor, Kristi Graves, Suzanne O’Neill, David Kim, Marc D. Schwartz
Public Health Genomics.2024; 27(1): 100. CrossRef
Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis
Muhammad Danyal Ahsan, Isabelle R. Chandler, Samantha Min, Benjamin Grant, Michelle Primiano, Jamieson Greenwald, Tamar N. Soussana, Becky Baltich Nelson, Charlene Thomas, Eloise Chapman-Davis, Ravi N. Sharaf, Melissa K. Frey
Clinical Obstetrics & Gynecology.2024; 67(4): 702. CrossRef
Prevalence and spectrum of pathogenic variants among patients with multiple primary cancers evaluated by clinical characteristics
Brittany L. Bychkovsky, Min‐Tzu Lo, Amal Yussuf, Carrie Horton, Marcy Richardson, Holly LaDuca, Judy E. Garber, Huma Q. Rana
Cancer.2022; 128(6): 1275. CrossRef
Health equity in the implementation of genomics and precision medicine: A public health imperative
Muin J. Khoury, Scott Bowen, W. David Dotson, Emily Drzymalla, Ridgely F. Green, Robert Goldstein, Katherine Kolor, Leandris C. Liburd, Laurence S. Sperling, Rebecca Bunnell
Genetics in Medicine.2022; 24(8): 1630. CrossRef
Cascade Testing for Hereditary Cancer Syndromes: Should We Move Toward Direct Relative Contact? A Systematic Review and Meta-Analysis
Melissa K. Frey, Muhammad Danyal Ahsan, Hannah Bergeron, Jenny Lin, Xuan Li, Rana K. Fowlkes, Priyanka Narayan, Roni Nitecki, Jose Alejandro Rauh-Hain, Haley A. Moss, Becky Baltich Nelson, Charlene Thomas, Paul J. Christos, Jada G. Hamilton, Eloise Chapma
Journal of Clinical Oncology.2022; 40(35): 4129. CrossRef
Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care—Checking CHEK2
Brittany L. Bychkovsky, Nihat B. Agaoglu, Carolyn Horton, Jing Zhou, Amal Yussuf, Parichehr Hemyari, Marcy E. Richardson, Colin Young, Holly LaDuca, Deborah L. McGuinness, Rochelle Scheib, Judy E. Garber, Huma Q. Rana
JAMA Oncology.2022; 8(11): 1598. CrossRef

6,647 View
152 Download
9 Web of Science
9 Crossref

Type-Specific Viral Load and Physical State of HPV Type 16, 18, and 58 as Diagnostic Biomarkers for High-Grade Squamous Intraepithelial Lesions or Cervical Cancer: Jongseung Kim, Bu Kyung Kim, Dongsoo Jeon, Chae Hyeong Lee, Ju-Won Roh, Joo-Young Kim, Sang-Yoon Park; Cancer Res Treat. 2020;52(2):396-405. Published online August 28, 2019; DOI: https://doi.org/10.4143/crt.2019.152

Abstract PDF Supplementary Material PubReader ePub

Purpose
High rate of false-positive tests is a major obstacle to use human papillomavirus (HPV) detection as a diagnostic tool for high-grade squamous intraepithelial lesions or cervical cancer (HSIL+). We investigated whether type-specific viral load or physical state of HPV 16, 18, and 58 are useful biomarkers for HSIL+.
Materials and Methods
Type-specific viral loads of E6 and E2 genes in cervical cells from 240, 83, and 79 HPV 16–, 18–, and 58–infected women, respectively, were determined using real-time polymerase chain reaction. Viral loads were normalized to cellular DNA (copy/cell). Total and integrated viral loads and physical state were compared between HSIL+ and controls, and diagnostic value was determined using receiver operating characteristic analysis.
Results
Viral loads of HPV 16, 18, and 58 were significantly different in lesions in the same pathologic grade. High type-specific total viral loads were significantly associated with HSIL+ (odds ratio [OR], 14.065, 39.472, and 7.103 for HPV 16, 18, and 58, respectively). High integrated viral load was related to HSIL+ in women with HPV 16 (OR, 8.242), and integrated state was associated with HSIL+ in women with HPV 18 (OR, 9.443). Type-specific total viral load was significantly associated with HSIL+ (area under curve, 0.914, 0.937, and 0.971 for HPV 16, 18, and 58, respectively), indicating an excellent performance in detecting HSIL+.
Conclusion
Type-specific total viral load may be a powerful diagnostic marker for HSIL+ in HPV 16–, 18–, and 58–infected HSIL+ lesions. If demonstrated in all other high-risk HPV types, this method can lead to a paradigm shift in the strategy of equivocal cytologic abnormalities.

Citations

Citations to this article as recorded by

Correlation of different HPV genotype viral loads and cervical lesions: A retrospective analysis of 1585 cases
Yilu Zhou, Jiaxin Liu, Shuai Chen, Xianzhen Xin, Mohan Xiao, Xian Qiang, Lina Zhang
Cancer Cytopathology.2025;[Epub] CrossRef
Analysis of HPV-16 viral load, integration status, and p16 expression in relation to EBV co-infection and cervical lesion severity
Azam Khamseh, Ali Farhadi, Somayeh Jalilvand, Fariba Yarandi, Narges Izadi-Mood, Saied Ghorbani, Hassan Saadati, Elham Shirali, Seyed Mohammad Jazayeri, Jamal Sarvari
Scientific Reports.2025;[Epub] CrossRef
Progress in the Study of Cervical Cancer Screening Methods
祺孙
Advances in Clinical Medicine.2025; 15(03): 1989. CrossRef
Electrochemical Duplex Detection of E2 and E6 Genes of Human Papillomavirus Type 16 and Determination of Physical Status in High‐Risk Cervical Carcinoma
Sinthu Karunaithas, Thanyarat Chaibun, Patutong Chatchawal, Chamras Promptmas, Waranun Buajeeb, Lee Su Yin, Patcharee Jearanaikoon, Benchaporn Lertanantawong
Journal of Medical Virology.2025;[Epub] CrossRef
HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010–2021): a retrospective study
Yoo Jin Na, Oeuk Jeong, Jaehyun Seong, JeongGyu Lee, So Young Lee, Sooyoung Hur, Sangmi Ryou
Journal of Gynecologic Oncology.2024;[Epub] CrossRef
Evaluation of human papillomavirus type 16 viral load and genome physical status in Iranian women with cervical disease
Shadi Setayeshi, Ali Hasanzadeh, Yousef Yahyapour, Ahad Alizadeh, Hossein Ghorbani, Fahimeh Nokhostin, Meghdad Bagheri, Farzin Sadeghi
Molecular Biology Reports.2024;[Epub] CrossRef
Biomarkers in the Screening and Management of Cervical Cancer
Pallavi Punhani, Charanjeet Ahluwalia
Journal of Colposcopy and Lower Genital Tract Pathology.2024; 2(1): 6. CrossRef
Prevalence of Carcinogenic Genotypes of HPV-Infected Women in a Ten-Year Period (2014–2023) in Vojvodina, Serbia
Natasa Nikolic, Branka Basica, Mirjana Strbac, Lidija Terzic, Aleksandra Patic, Gordana Kovacevic, Radmila Velicki, Dusan Petrovic, Aljosa Mandic, Vladimir Petrovic
Medicina.2024; 60(6): 922. CrossRef
Increased human papillomavirus viral load is correlated to higher severity of cervical disease and poorer clinical outcome: A systematic review
Seth‐Frerich Fobian, Xionge Mei, Johannes Crezee, Barbara C. Snoek, Renske D. M. Steenbergen, Jiafen Hu, Timo L. M. ten Hagen, Louis Vermeulen, Lukas J. A. Stalpers, Arlene L. Oei
Journal of Medical Virology.2024;[Epub] CrossRef
The Diagnostic Significance of Combined Screening and Human Papillomavirus 16 and 18 Cycle Threshold Values for CIN2+ Cervical Lesions
Xue Bai, Ya-Kun Liu, Ya-Jing Jia, Dao-Juan Li, Nai-Yi Du
International Journal of Women's Health.2024; Volume 16: 1959. CrossRef
Evaluation of Human Papilloma Virus (HPV) Genotyping and Viral Load Determination as Diagnostic Biomarkers of Cervical Cancer Risk
Marianna Martinelli, Chiara Giubbi, Laura Saderi, Rosario Musumeci, Federica Perdoni, Biagio Eugenio Leone, Robert Fruscio, Fabio Landoni, Andrea Piana, Giovanni Sotgiu, Clementina Elvezia Cocuzza
International Journal of Molecular Sciences.2023; 24(2): 1320. CrossRef
Implications of viral infections and oncogenesis in uterine cervical carcinoma etiology and pathogenesis
Daming Chu, Tengteng Liu, Yuan Yao
Frontiers in Microbiology.2023;[Epub] CrossRef
Prevalence and Risk Factors for High-Risk Human Papillomavirus Infection and Cervical Disorders: Baseline Findings From an Human Papillomavirus Cohort Study
Paula Saldaña-Rodríguez, Margarita Bahena-Román, Karina Delgado-Romero, Vicente Madrid-Marina, Kirvis Torres-Poveda
Cancer Control.2023;[Epub] CrossRef
A Review of the Application of Heterostructure Catalysts in Hydrogen Evolution Reaction
Shizhi Dong, Yanshuai Li, Zhilong Zhao, Ruichuan Li, Jiaqi He, Jinpeng Yin, Bing Yan, Xing Zhang
ChemistrySelect.2022;[Epub] CrossRef
The frequency of infection with high-risk human papilloma virus types on the cervix uteri of women of reproductive age
Jovana Prelić, Aleksandra Knežević
Medicinski podmladak.2022; 73(1): 55. CrossRef
Influence of Lacidophilin Vaginal Capsules plus rh-IFN-α2b on Efficacy, Vaginal Microecology, and Safety of Patients with HPV Infection
Yan Sun, Jianqun Xu, Hongya Zhou, Lina You, Yan Zhu, Shoib Baba
Evidence-Based Complementary and Alternative Medicine.2022; 2022: 1. CrossRef
Comparison of cycle threshold values of the Cobas HPV test and viral loads of the BMRT HPV test in cervical cancer screening
Qing Yang, Hui Du, Xinfeng Qu, Wenkui Dai, Liming Gui, Changzhong Li, Chun Wang, Chunlei Guo, Yi Zhang, Lihui Wei, J. L. Belinson, Ruifang Wu
Frontiers in Public Health.2022;[Epub] CrossRef
EGFR Protein Expression Relates with Tumor Histology, Methylation Status of EGFR and HPV16 E6 Viral Load in Oropharyngeal Carcinoma
Yo Suzuki, Yuki Fukumura, Miki Asahina, Mitsuhisa Fujimaki, Shinichi Ohba, Fumihiko Matsumoto, Isao Kurahayashi, Takashi Yao, Katsuhisa Ikeda
Head and Neck Pathology.2021; 15(3): 743. CrossRef
Detection of 14 High-Risk Human Papillomaviruses Using Digital LAMP Assays on a Self-Digitization Chip
Jiasi Wang, Jeannette P. Staheli, Andrew Wu, Jason E. Kreutz, Qiongzheng Hu, Jingang Wang, Thomas Schneider, Bryant S. Fujimoto, Yuling Qin, Gloria S. Yen, Bob Weng, Kara Shibley, Halia Haynes, Rachel L. Winer, Qinghua Feng, Daniel T. Chiu
Analytical Chemistry.2021; 93(6): 3266. CrossRef
Viral load and high prevalence of HR-HPV52 and 58 types in black women from rural communities
Lays Paula Bondi Volpini, Jerusa Araújo Dias, Luciana Bueno de Freitas, Maria Carmen Lopes Ferreira Silva, Angélica Espinosa Miranda, Liliana Cruz Spano
BMC Infectious Diseases.2021;[Epub] CrossRef
Significance of HPV16 Viral Load Testing in Anal Cancer
Ewa Małusecka, Ewa Chmielik, Rafał Suwiński, Monika Giglok, Dariusz Lange, Tomasz Rutkowski, Agnieszka M. Mazurek
Pathology & Oncology Research.2020; 26(4): 2191. CrossRef
Cervical cancer risk profiling: molecular biomarkers predicting the outcome of hrHPV infection
Mariano A Molina, Ludovica Carosi Diatricch, Marina Castany Quintana, Willem JG Melchers, Karolina M Andralojc
Expert Review of Molecular Diagnostics.2020; 20(11): 1099. CrossRef
MicroRNA-Based Fingerprinting of Cervical Lesions and Cancer
Justyna Pisarska, Katarzyna Baldy-Chudzik
Journal of Clinical Medicine.2020; 9(11): 3668. CrossRef

11,031 View
314 Download
23 Web of Science
23 Crossref

Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers: Eun-Gyeong Lee, Hyok Jo Kang, Myong Cheol Lim, Boyoung Park, Soo Jin Park, So-Youn Jung, Seeyoun Lee, Han-Sung Kang, Sang-Yoon Park, Boram Park, Jungnam Joo, Jai Hong Han, Sun-Young Kong, Eun Sook Lee; Cancer Res Treat. 2019;51(1):280-288. Published online May 4, 2018; DOI: https://doi.org/10.4143/crt.2018.079

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to investigate decision patterns to reduce the risks of BRCArelated breast and gynecologic cancers in carriers of BRCA pathogenic variants. We found a change in risk-reducing (RR) management patterns after December 2012, when the National Health Insurance System (NHIS) of Korea began to pay for BRCA testing and riskreducing salpingo-oophorectomy (RRSO) in pathogenic-variant carriers.
Materials and Methods
The study group consisted of 992 patients, including 705 with breast cancer (BC), 23 with ovarian cancer (OC), 10 with both, and 254 relatives of high-risk patients who underwent BRCA testing at the National Cancer Center of Korea from January 2008 to December 2016.We analyzed patterns of and factors in RR management.
Results
Of the 992 patients, 220 (22.2%) were carriers of BRCA pathogenic variants. About 92.3% (203/220) had a family history of BC and/or OC,which significantly differed between BRCA1 and BRCA2 carriers (p < 0.001). All 41 male carriers chose surveillance. Of the 179 female carriers, 59 of the 83 carriers (71.1%) with BC and the 39 of 79 unaffected carriers (49.4%) underwent RR management. None of the carriers affected with OC underwent RR management. Of the management types, RRSO had the highest rate (42.5%) of patient choice. The rate of RR surgery was significantly higher after 2013 than before 2013 (46.3% [74/160] vs. 31.6% [6/19], p < 0.001).
Conclusion
RRSO was the preferred management for carriers of BRCA pathogenic variants. The most important factors in treatment choice were NHIS reimbursement and/or the severity of illness.

Citations

Citations to this article as recorded by

A Scoping Review of Primary Breast Cancer Risk Reduction Strategies in East and Southeast Asia
Filipa Alpeza, Christine Kim Yan Loo, Qingyuan Zhuang, Mikael Hartman, Serene Si Ning Goh, Jingmei Li
Cancers.2025; 17(2): 168. CrossRef
Risk-reducing decisions regarding germlineBRCApathogenic variant: focusing on the timing of genetic testing and RRSO
Akiko Abe, Hidetaka Nomura, Atsushi Fusegi, Mayu Yunokawa, Arisa Ueki, Eri Habano, Hiromi Arakawa, Keika Kaneko, Yuko Minoura, Hitoshi Inari, Takayuki Ueno, Hiroyuki Kanao
Journal of Medical Genetics.2024; 61(4): 392. CrossRef
BRCA Mutation Patients: Are There Other Predisposing Factors for Ovarian Cancer Occurrence? A Multicenter Retrospective Study
Vera Loizzi, Michele Mongelli, Francesca Arezzo, Isabella Romagno, Gerardo Cazzato, Ondina Popescu, Francesco Legge, Paolo Trerotoli, Erica Silvestris, Anila Kardhashi, Gennaro Cormio
Gynecologic and Obstetric Investigation.2024; 89(2): 87. CrossRef
Implementation of BRCA Test among Young Breast Cancer Patients in South Korea: A Nationwide Cohort Study
Yung-Huyn Hwang, Tae-Kyung Yoo, Sae Byul Lee, Jisun Kim, Beom Seok Ko, Hee Jeong Kim, Jong Won Lee, Byung Ho Son, Il Yong Chung
Cancer Research and Treatment.2024; 56(3): 802. CrossRef
Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean BRCA1/2 Mutation Carriers
Dabin Kim, Jai Min Ryu, Sang-Ah Han, Zisun Kim, Sung-Won Kim
Current Oncology.2024; 31(11): 6767. CrossRef
Impact of graphical display on the intention to undergo risk-reducing salpingo-oophorectomy and mastectomy in individuals positive for BRCA pathogenic variant
Yoon-Jung Choi, Younju Park, Boyoung Park, Heejung Chae, So-Youn Jung, Kum Hei Ryu, Myong Cheol Lim, Soo Jin Park, Yoon Jung Chang, Sun-Young Kong
Scientific Reports.2024;[Epub] CrossRef
Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan
Hidetaka Nomura, Akiko Abe, Atsushi Fusegi, Teruyuki Yoshimitsu, Satoki Misaka, Atsushi Murakami, Tsuyoshi Matsumoto, Shiho Tsumura, Motoko Kanno, Yoichi Aoki, Sachiho Netsu, Makiko Omi, Terumi Tanigawa, Sanshiro Okamoto, Kohei Omatsu, Mayu Yunokawa, Hiro
Scientific Reports.2023;[Epub] CrossRef
Characteristics of second primary breast cancer after ovarian cancer: a Korea central cancer registry retrospective study
Eun-Gyeong Lee, Jiwon Lim, Hyeong In Ha, Myong Cheol Lim, Yoon Jung Chang, Young-Joo Won, So-Youn Jung
Frontiers in Oncology.2023;[Epub] CrossRef
Differences in Willingness to Undergo BRCA1/2 Testing and Risk Reducing Surgery among the General Public, Cancer Patients, and Healthcare Professionals: A Large Population-Based Survey
Yoon Jung Chang, Seungyeon Cho, Jungnam Joo, Kum Hei Ryu, Sangwon Lee, Juhee Cho, Myong Cheol Lim, So-Youn Jung, Jai Hong Han, Eun Sook Lee, Sun-Young Kong
Journal of Personalized Medicine.2022; 12(5): 818. CrossRef
Management of patients with BRCA mutation from the point of view of a breast surgeon
M.L. Riis
Annals of Medicine and Surgery.2021; 65: 102311. CrossRef
Disparities between Uptake of Germline BRCA1/2 Gene Tests and Implementation of Post-test Management Strategies in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
Young Min Hur, Jaehee Mun, Mi-Kyung Kim, Maria Lee, Yun Hwan Kim, Seung-Cheol Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef
Clinical significance of gene polymorphisms for hereditary predisposition to breast and ovarian cancer (review of literature)
D. I. Vodolazhsky, A. V. Mayakovskaya, A. V. Kubyshkin, K. A. Aliev, I. I. Fomochkina
Russian Clinical Laboratory Diagnostics.2021; 66(12): 760. CrossRef
Trends in Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy in Korean Carriers of the BRCA1/2 Mutation
Sung Mi Jung, Jai Min Ryu, Hyung Seok Park, Ji Soo Park, Eunyoung Kang, Seeyoun Lee, Han-Byoel Lee, Hyun Jo Youn, Tae-Kyung Yoo, Jisun Kim, Jeong Eon Lee, Sang Ah Han, Dongwon Kim, Sung-Won Kim
Journal of Breast Cancer.2020; 23(6): 647. CrossRef

11,207 View
232 Download
15 Web of Science
13 Crossref

Comparison of Quality of Life and Sexuality between Cervical Cancer Survivors and Healthy Women: Yumi Lee, Myong Cheol Lim, Se Ik Kim, Jungnam Joo, Dong Ock Lee, Sang-Yoon Park; Cancer Res Treat. 2016;48(4):1321-1329. Published online February 12, 2016; DOI: https://doi.org/10.4143/crt.2015.425

Abstract PDF PubReader ePub

Purpose
The purpose of this study is to compare quality of life (QoL) and sexual functioning between sexually active cervical cancer survivors and healthy women.
Materials and Methods
In this cross-sectional study, propensity-score-matched cervical cancer survivors (n=104) and healthy women (n=104) were compared. All women had engaged in sexual activity within the previous 3 months, and cervical cancer survivors showed no evidence of disease after primary treatment. QoL and sexual functioning were assessed using three questionnaires; the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), Cervical Cancer Module (EORTC QLQ-CX24), and the Female Sexual Function Index (FSFI).
Results
Significantly higher scores for lymphedema were observed in the cervical cancer survivors group compared with the healthy women group (mean, 20.2 vs. 12.2; p < 0.05). Sexuality, both in terms of sexual activity, sexual enjoyment, and sexual worry (EORTC QLQ-CX24), and in terms of desire, arousal, lubrication, orgasm, satisfaction, and pain (FSFI) were similar between the groups. When the scale of sexual/vaginal functioning in EORTC QLQ-CX24 was divided into individual questions, cervical cancer survivors reported shorter vaginal length than the control group, but without statistical significance (mean, 80.6 vs. 85.4; p=0.077).
Conclusion
Compared with healthy women, sexuality was not impaired in cervical cancer survivors who showed no evidence of disease after primary treatment and engaging in sexual activity. Further prospective cohort studies are warranted to confirm this finding.

Citations

Citations to this article as recorded by

Longitudinal study on quality of life following cervical cancer treatment in Botswana
Surbhi Grover, Rohini K Bhatia, Salman Khan, Paseka Tladi, Lesego Gabaitiri, Memory Bvochora-Nsingo, Sebathu Chiyapo, Dawn Balang, Shalini Vinod, Mark N Polizzotto, Natalie Taylor, Karen Canfell, Nicola Zetola, Doreen Ramogola-Masire, Lilie L Lin, Erle Ro
BMJ Global Health.2025; 10(3): e017206. CrossRef
The feasibility and acceptability of delivering and evaluating a physical activity intervention (ACCEPTANCE) for cervical cancer survivors
Nessa Millet, Hilary J. McDermott, Fehmidah Munir, Charlotte L. Edwardson, Tatiana Plekhanova, Esther L. Moss
Pilot and Feasibility Studies.2025;[Epub] CrossRef
Sexual quality of life between healthy women and women with gynecological cancer: Results of a hospital‐based case–control study in Türkiye
Ekin Dila Topaloğlu Ören, Selin Kiziltaş
Journal of Obstetrics and Gynaecology Research.2024; 50(3): 456. CrossRef
Quality of life in long-term cervical cancer survivors compared with healthy women and women with benign gynecological disorders
Jorge Cea García, Inmaculada Rodríguez Jiménez, Francisco Márquez Maraver, Laura Ríos-Pena, M. Carmen Rubio Rodríguez
European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 297: 78. CrossRef
Pre- and Post-Treatment Quality of Life Among Patients with Advanced Stage Cervical Cancer at Tikur Anbessa Specialized Hospital, Ethiopia
Roza Teshome, Irene Yang, Edom Woldetsadik, Eshetu Girma, Melinda Higgins, Jessica Wells
Cancer Management and Research.2024; Volume 16: 311. CrossRef
Female sexual function in long-term cervical cancer survivors compared with healthy women and women affected by benign gynecological disorders
Jorge Cea García, Francisco Márquez Maraver, Inmaculada Rodríguez Jiménez, Laura Ríos-Pena, M. Carmen Rubio Rodríguez
European Journal of Obstetrics & Gynecology and Reproductive Biology.2024; 299: 43. CrossRef
Prevalence of sexual dysfunction in women with cervical cancer: a systematic review and meta-analysis
Maolin Qian, Lan Wang, Jiajun Xing, Xiao Shan, Juan Wu, Xiaoqin Liu
Psychology, Health & Medicine.2023; 28(2): 494. CrossRef
Trends and future projections of cervical cancer‐related outcomes in Japan: What happens if the HPV vaccine program is not implemented?
Atsuko Sakakibara, Takeo Nakayama, Hiroyuki Uchida, Youichi Odagiri, Yuri Ito, Toshiro Katayama, Yutaka Ueda, Toshihiro Higuchi, Koichi Terakawa, Kunihiko Matsui, Kikuko Miyazaki, Ikuo Konishi
International Journal of Cancer.2023; 152(9): 1863. CrossRef
Post Treatment Sexual Function and Quality of Life of Patients Affected by Cervical Cancer: A Systematic Review
Stefano Cianci, Mattia Tarascio, Martina Arcieri, Marco La Verde, Canio Martinelli, Vito Andrea Capozzi, Vittorio Palmara, Ferdinando Gulino, Salvatore Gueli Alletti, Giuseppe Caruso, Stefano Restaino, Giuseppe Vizzielli, Carmine Conte, Marco Palumbo, Alf
Medicina.2023; 59(4): 704. CrossRef
Association between cervical cancer-related anxiety and depression symptoms and health-related quality of life: A Moroccan cross-sectional study
Asmaa Azizi, Doha Achak, Amal Boutib, Samia Chergaoui, Elmadani Saad, Abderraouf Hilali, Amr S. Soliman, Ibtissam Youlyouz-Marfak, Abdelghafour Marfak
Clinical Epidemiology and Global Health.2023; 22: 101328. CrossRef
Impacto del cáncer de cuello uterino en la sexualidad femenina
Camilla R. Albæk-Jakobsen, Pere Fusté-Brull
Medicina.2023; 24(2): 21. CrossRef
Sexual Behaviors and Intimate Relationships of Sexual Partners of Young Patients with Early-Stage Cervical Cancer: A Qualitative Study
Mingyue Li, Dongyang Wang, Jiaxiang Huang, Shunlian Luan, Qinghua Wang
International Journal of General Medicine.2023; Volume 16: 5377. CrossRef
Long-term Quality of Life and Sexual Function After Neoadjuvant Chemotherapy and Radical Surgery for Locally Advanced Cervical Cancer
Innocenza Palaia, Giusi Santangelo, Giuseppe Caruso, Giorgia Perniola, Valentina Tibaldi, Ludovico Muzii, Pierluigi Benedetti Panici, Violante Di Donato
The Journal of Sexual Medicine.2022; 19(4): 613. CrossRef
The Importance of Social Support, Optimism and Resilience on the Quality of Life of Cancer Patients
Iván Ruiz-Rodríguez, Isabel Hombrados-Mendieta, Anabel Melguizo-Garín, María José Martos-Méndez
Frontiers in Psychology.2022;[Epub] CrossRef
Relationship of sexual quality of life and mental well-being in undergraduate women in a Canadian university
Niki Oveisi, Zeba Khan, Lori A. Brotto
The Canadian Journal of Human Sexuality.2022; 31(3): 422. CrossRef
Longitudinal Health-Related Quality of Life Study among Cervical Cancer Patients Treated with Radiotherapy
Małgorzata Pasek, Lilia Suchocka, Grażyna Osuch-Pęcak, Konrad Muzykiewicz, Ewa Iwańska, Helena Kaducakowa, Anna Goździalska, Magdalena Goździalska
Journal of Clinical Medicine.2021; 10(2): 226. CrossRef
Sexual Function and the Role of Sexual Communication in Women Diagnosed with Cervical Cancer: A Systematic Review
Magdalena Liberacka-Dwojak, Paweł Izdebski
International Journal of Sexual Health.2021; 33(3): 385. CrossRef
Contribution of Sociodemographic, Clinical, and Psychological Variables to Quality of Life in Women with Cervical Cancer in the Follow-Up Phase
Ana Clara Lopes, Rosário Bacalhau, Martim Santos, Marta Pereira, M. Graça Pereira
Journal of Clinical Psychology in Medical Settings.2020; 27(3): 603. CrossRef
Health-related quality of life and associated factors among cervical cancer patients at Tikur Anbessa specialized hospital, Addis Ababa, Ethiopia
Liya Teklu Araya, Teferi Gedif Fenta, Beate Sander, Girma Tekle Gebremariam, Gebremedhin Beedemariam Gebretekle
Health and Quality of Life Outcomes.2020;[Epub] CrossRef
Le retentissement du cancer utérin et ses traitements sur la sexualité
A. Ghorbel, A. Yousfi, R. Abidi, S. Yahyaoui, S. Zaraa, K. Mahjoubi, A. Belaid, W. Gargouri, C. Nasr
Sexologies.2020; 29(4): 186. CrossRef
Survey of the desire to have children and engage in sexual activity after trachelectomy among young Japanese women with early‐stage cervical cancer
Hideaki Yahata, Kenzo Sonoda, Kaoru Okugawa, Hiroshi Yagi, Tatsuhiro Ohgami, Masafumi Yasunaga, Ichiro Onoyama, Eisuke Kaneki, Kazuo Asanoma, Kiyoko Kato
Journal of Obstetrics and Gynaecology Research.2019; 45(11): 2255. CrossRef
Qualidade de vida e fatores associados em mulheres sobreviventes ao câncer do colo do útero
Camila Soares Lima Corrêa, Isabel Cristina Gonçalves Leite, Anna Paula Silva Andrade, Simone Meira Carvalho, Ricardo Miranda Borges, Maximiliano Ribeiro Guerra
HU Revista.2019; 43(4): 307. CrossRef
The EOLO (End-of-Life Ovarian Cancer) Study: Approach to Ovarian Cancer Patients at the End of Life
Innocenza Palaia, Federica Tomao, Giusi Santangelo, Anna Di Pinto, Carolina Maria Sassu, Giorgia Perniola, Angela Musella, Violante Di Donato, Antonella Giancotti, Pierluigi Benedetti Panici
Oncology.2019; 97(5): 306. CrossRef
Vaginal development and sexual functioning in young women after stem cell transplantation, chemotherapy, and/or radiotherapy for childhood hematological diseases
Fausta Beneventi, Elena Locatelli, Margherita Simonetta, Chiara Cavagnoli, Raffaella Pampuri, Camilla Bellingeri, Irene De Maggio, Beatrice Ruspini, Santina Recupero, Giovanna Giorgiani, Arsenio Spinillo
Bone Marrow Transplantation.2018; 53(9): 1157. CrossRef
Cross-cultural adaptation and validation of the Functional Assessment of Chronic Illness Therapy – Cervical Dysplasia (FACIT-CD) questionnaire for Serbian women
Vesna Kesić, Radmila Sparić, Rafal Watrowski, Jelena Dotlić, Radomir Stefanović, Gorica Marić, Tatjana Pekmezović
European Journal of Obstetrics & Gynecology and Reproductive Biology.2018; 226: 7. CrossRef
Percutaneous parametrial dose escalation in women with advanced cervical cancer: feasibility and efficacy in relation to long-term quality of life
Sati Akbaba, Jan Tobias Oelmann-Avendano, Tilman Bostel, Harald Rief, Nils Henrik Nicolay, Juergen Debus, Katja Lindel, Robert Foerster
Radiology and Oncology.2018; 52(3): 320. CrossRef
Attitudes Regarding HPV Vaccinations of Children among Mothers with Adolescent Daughters in Korea
Kyong-No Lee, Kylie Hae-Jin Chang, Seong-Sik Cho, Sung-Ho Park, Sung Taek Park
Journal of Korean Medical Science.2017; 32(1): 130. CrossRef
Impact of Ospemifene on Quality of Life and Sexual Function in Young Survivors of Cervical Cancer: A Prospective Study
Nicoletta De Rosa, Giada Lavitola, Pierluigi Giampaolino, Ilaria Morra, Carmine Nappi, Giuseppe Bifulco
BioMed Research International.2017; 2017: 1. CrossRef
Körperliche Beschwerden und psychosoziale Folgen nach einer Zervixkarzinomerkrankung
Kristina Geue, Elisabeth Sowa, Susanne Kuhnt
Der Onkologe.2016; 22(10): 780. CrossRef

13,672 View
393 Download
33 Web of Science
29 Crossref

Second Primary Cancer after Diagnosis and Treatment of Cervical Cancer: Myong Cheol Lim, Young-Joo Won, Jiwon Lim, Yeon-Joo Kim, Sang Soo Seo, Sokbom Kang, Eun Sook Lee, Jae Hwan Oh, Joo-Young Kim, Sang-Yoon Park; Cancer Res Treat. 2016;48(2):641-649. Published online July 17, 2015; DOI: https://doi.org/10.4143/crt.2014.326

Abstract PDF PubReader ePub

Purpose
This study was conducted to investigate the incidence and survival outcomes of second primary cancers after the diagnosis of cervical cancer.
Materials and Methods
Data from the Korea Central Cancer Registry between 1993 and 2010 were reviewed and analyzed. Standardized incidence ratios (SIRs) of second primary cancers among women with cervical cancer were analyzed. Kaplan-Meier survival curves were constructed for cervical cancer patients with or without a second primary cancer.
Results
Among 72,805 women with cervical cancer, 2,678 (3.68%) developed a second primary cancer within a mean follow-up period of 7.34 years. The overall SIR for a second cancer was 1.08 (95% confidence interval, 1.04 to 1.12). The most frequent sites of second primary cancers were the vagina, bone and joints, vulva, anus, bladder, lung and bronchus, corpus uteri, and esophagus. However, the incidence rates of four second primary cancers (breast, rectum, liver, and brain) were decreased. The 5-year and 10-year overall survival rates were 78.3% and 72.7% in all women with cervical cancer, and for women with a second primary cancer, these rates were 83.2% and 65.5% from the onset of cervical cancer and 54.9% and 46.7% from the onset of the second primary cancer, respectively.
Conclusion
The incidence rates of second primary cancers were increased in women with cervical cancer compared to the general population, with the exception of four decreasing cancers. The 10-year overall survival rates were decreased in cervical cancer patients with a second primary cancer.

Citations

Citations to this article as recorded by

Temporal trends in the incidence of second primary cancers in Northern Portugal: a population-based study
Elisabete Gonçalves, Filipa Fontes, Jéssica Rocha Rodrigues, Luis Antunes, Maria José Bento, Nuno Lunet, Samantha Morais
European Journal of Cancer Prevention.2025;[Epub] CrossRef
The risk for subsequent primary lung cancer after cervical carcinoma: A quantitative analysis based on 864,627 cases
Sheng Gong, Gang Li, Dan Li, Yu Liu, Banggui Wu, Yan Wang
PLOS ONE.2024; 19(6): e0305670. CrossRef
Increased risk of subsequent primary lung cancer among female hormone-related cancer patients: A meta-analysis based on over four million cases
Yan Wang, Wenpeng Song, Haoyu Wang, Guonian Zhu, Yangqian Li, Zhoufeng Wang, Weimin Li, Guowei Che
Chinese Medical Journal.2024; 137(15): 1790. CrossRef
Association between radiation therapy for primary endometrial cancer and risk of second primary malignancies: a retrospective cohort study
Yuebo Wang, Yanan Cai
Scientific Reports.2024;[Epub] CrossRef
Nomograms constructed for predicting diagnosis and prognosis in cervical cancer patients with second primary malignancies: a SEER database analysis
Ning Xie, Jie Lin, Linying Liu, Sufang Deng, Haijuan Yu, Yang Sun
Journal of Cancer Research and Clinical Oncology.2023; 149(14): 13201. CrossRef
Differences of characteristics, influencing factors, and treatment effects on the survival in patients with first and second primary cervical cancer
Fan Zhang, Ping Yu, Lixia Xu, Xuwei Chen, Junqiang Du
Preventive Medicine Reports.2023; 36: 102504. CrossRef
Second primary malignancies in cervical cancer and endometrial cancer survivors: a population-based analysis
Kejie Huang, Lijuan Xu, Mingfang Jia, Wenmin Liu, Shijie Wang, Jianglong Han, Yanbo Li, Qibin Song, Zhenming Fu
Aging.2022; 14(9): 3836. CrossRef
Second Malignancies Following Primary Cervical Cancer Diagnosis: Analysis of the SEER Database
Oluwasegun A Akinyemi, Faith O Abodunrin, Tsion F Andine, Kindha Elleissy Nasef, Bolarinwa Akinwumi, Ayobami Oduwole, Christina Lipscombe, Ademola S Ojo, Mary Fakorede
Cureus.2022;[Epub] CrossRef
Conditional relative survival of cervical cancer: a Korean National Cancer Registry Study
Dong Wook Shin, Jaeman Bae, Johyun Ha, Kyu-Won Jung
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
MicroRNAs expression analysis shows key affirmation of Synaptopodin-2 as a novel prognostic and therapeutic biomarker for colorectal and cervical cancers
Md. Shahadat Hossain, Mahafujul Islam Quadery Tonmoy, Md. Nur Islam, Md. Sajedul Islam, Ibrahim Khalil Afif, Arpita Singha Roy, Atqiya Fariha, Hasan Al Reza, Newaz Mohammed Bahadur, Md. Mizanur Rahaman
Heliyon.2021; 7(6): e07347. CrossRef
Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis
Duncan C. Gilbert, Katie Wakeham, Ruth E. Langley, Claire L. Vale
British Journal of Cancer.2019; 120(2): 256. CrossRef
Leiomyosarcoma of the Rectum as a Radiation-Induced Second Malignancy after Cervical Cancer Treatment: Case Report with Review of the Literature
Dmytro E. Makhmudov, Olena O. Kolesnik, Natalia N. Lagoda, Maryna O. Volk
Case Reports in Oncological Medicine.2019; 2019: 1. CrossRef
Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis
Koji Matsuo, Erin A. Blake, Hiroko Machida, Rachel S. Mandelbaum, Lynda D. Roman, Jason D. Wright
Gynecologic Oncology.2018; 150(3): 501. CrossRef
Investigation of tumor-tumor interactions in a double human cervical carcinoma xenograft model in nude mice
Barbara Mertens, Tatiane Cristina de Araujo Nogueira, Dimitrios Topalis, Ruzena Stranska, Robert Snoeck, Graciela Andrei
Oncotarget.2018; 9(31): 21978. CrossRef
Elevated risk of human papillomavirus‐related second cancers in survivors of anal canal cancer
Rebecca A. Nelson, Lily L. Lai
Cancer.2017; 123(20): 4013. CrossRef

14,576 View
136 Download
21 Web of Science
15 Crossref

First
Prev
Page of 1
Next
Last

Search